

# Datasheet




Mouse mAb to **CD74**  
Clone **LN-2**  
Isotype **IgG1-κ**

## Source

A BALB/c mouse was immunized with cell extracts from diffuse histiocytic lymphoma SU-DHL-4.  
Fusion partner: NS-1.

## Specifications

LN-2 is directed against the CD74 cluster, established during the IV<sup>th</sup> Leukocyte Typing Workshops. CD74 comprises four species of proteins (MW 41/35/33 kDa), all coded by a single gene, consisting of nine exons. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. In tissue sections anti CD74 show a binding pattern very similar to that of anti-HLA-DR. It binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides.



**Figure 1:** Human tonsil stained with LN-2 (paraffin).

## Species reactivity

Positive: baboon, human, mouse.  
Negative: rat.

## Applications

LN-2 is used for identification of germinal center derived B-cell lymphomas, leukemias, diagnostic Reed-Sternberg cells and Hodgkin's cells. Anti-VD74 has been shown to be useful in differentiating atypical fibroxanthoma (-) from malignant fibrous histiocytoma (+).

Flow cytometry	Frozen sections	Immunofluorescence	Paraffin sections
+	+	+	Citrate

## Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.

Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

## Dilution advice

- Flow cytometry (0,5-1,0 µg/million cells in 0,1 ml).
- Immunofluorescence (0,5-1,0 µg/ml).
- Immunohistology (1-2 µg/ml for 30 min at RT; staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes).

## Positive control

Daudi or Raji cells. Tonsil or lymph node.

# Datasheet



## References

- Epstein A.L. et al. *J. Immunol.* **133**: 1028-1036 (1984).
- Marder, R.J. et al. *Lab. Invest.* **52**: 497-504 (1985).
- Lazova R. et al. *Cancer* **79**: 2115-2124 (1997).
- Pich, A. et al. *Eur J Basic Appl Histochem.* **35(1)**: 81-9 (1991).